Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Mar;2(2):57-66.
doi: 10.1200/JOP.2006.2.2.57.

Individualized strategy for dosing luteinizing hormone-releasing hormone agonists for androgen-independent prostate cancer: identification of outcomes and costs

Jennifer A Wagmiller  1 , Jennifer J Griggs, Andrew W Dick, Deepak M Sahasrabudhe
Affiliations

Individualized strategy for dosing luteinizing hormone-releasing hormone agonists for androgen-independent prostate cancer: identification of outcomes and costs

Jennifer A Wagmiller et al. J Oncol Pract. 2006 Mar.

Abstract

Purpose: Continuing androgen suppression is the current standard in men with androgen-independent prostate cancer (AIPC). An individualized strategy, wherein luteinizing hormone-releasing hormone agonists (LH-RHas) are redosed when serum testosterone approaches a non-castrate level, may decrease costs without worsening outcomes. To understand possible outcomes, we performed a cost-utility analysis comparing individualized and fixed LH-RHa dosing strategies in men with AIPC.

Methods: The model used a societal perspective, a 5-year time horizon, and 3% annual cost discounting. The model accounted for direct costs of androgen suppression. Utilities were varied in accordance with published preference data.

Results: Under base-case assumptions, individualized LH-RHa dosing yielded 1.089 expected quality-adjusted life years (QALYs), compared with 1.094 expected QALYs for fixed LH-RHa dosing. In cost analysis, lifetime per-patient costs for androgen suppression were estimated to be $5,694 for individualized LH-RHa dosing and $9,157 for fixed LH-RHa dosing. Applied to the total population, a strategy of individualized LH-RHa dosing would cost $170 million for androgen suppression, compared with $274 million for fixed LH-RHa dosing. Under these assumptions, adopting the individualized strategy resulted in $692,600 gained from a societal perspective for each QALY lost (the decremental cost utility).

Conclusion: The results suggest that an individualized LH-RHa dosing strategy would be associated with moderate savings on an individual basis but substantial savings on a population basis, and would not adversely affect quality of life or life expectancy. Further research is needed to establish the effects of this strategy on symptoms and survival, as well as patient satisfaction and true costs.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Possible androgen-suppression strategies.
Figure 2.
Figure 2.
Model for individualized androgen suppression strategy. LH-RHa, luteinizing hormone-reducing hormone agonist.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. American Cancer Society. Cancer Facts & Figures. 2004. http://www.cancer.org/downloads/STT/CAFF_finalPWSecured.pdf.
    1. Piper NY, Kusada L, Lance R, et al. Adenocarcinoma of the prostate: An expensive way to die. Prostate Cancer Prostatic Dis. 2002;5:164–166. - PubMed
    1. Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol. 1993;11:2167–2172. - PubMed
    1. Chon JK, Jacobs SC, Naslund MJ. The cost value of medical versus surgical hormonal therapy for metastatic prostate cancer. J Urol. 2000;64:735–737. - PubMed
    1. Hillner BE, Roberts JD. Role of perspective and other uncertainties in cost-effectiveness assessments in advanced prostate cancer. J Natl Cancer Inst. 2000;92:1704–1706. - PubMed

LinkOut - more resources